Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Published byLillian Fox Modified over 5 years ago

Similar presentations

Presentation on theme: "Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier."— Presentation transcript:

1 Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Survival analysis comparing outcomes in patients showing differential gene expression of (A) BRCA2 and (B) MMP9 that are associated with RAD001 good response and (C) BTC and (D) CHST3 that are associated with poor response to RAD001 treatment. Median count of gene expression level was taken as the threshold to determine the survival curve. PFS was used as the outcome metric. Kakoli Das et al. ESMO Open 2016;1:e000009 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier."

Similar presentations

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.
Oncol Res Treat 2016;39: DOI: /

Oncol Res Treat 2016;39: DOI: /
 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Gene expression profiles as measured by the NanoString nCounter System in 54 patients with metastatic gastric cancer (GC). Gene expression profiles as.

Gene expression profiles as measured by the NanoString nCounter System in 54 patients with metastatic gastric cancer (GC). Gene expression profiles as.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
The decision tree with the two alternatives.

The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
(A) Safety profile overview.

(A) Safety profile overview.
Overview of the QTWiST method

Overview of the QTWiST method
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
PRISMA study flow diagram

PRISMA study flow diagram
Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).
Kaplan-Meier curves for overall survival (OS) probability.

Kaplan-Meier curves for overall survival (OS) probability.
Methods distribution among the three EQAs

Methods distribution among the three EQAs

Similar presentations

Ads by Google